SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bob clark who wrote ()10/6/1999 2:26:00 AM
From: JerryR  Read Replies (1) of 1972
 
I inquired about the phase III trial of Allovectin-7 and received a response last week. IR stated that accrual will be completed by mid 2000. They expect it will take 6 months for collection and analysis of data. The FDA could take another 6 months(if they get fast track status). They do plan to take an interim look at data from patients already accrued by the end of 1999. Data and analysis will probably not be released, but they plan to disclose decisions based upon those data, perhaps in the first quarter of 2000. None of the above is written in stone. Jerry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News